Nuvelo Starts Phase II Trial Of Alfimeprase In Ischemic Stroke
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Nuvelo has begun a Phase II trial for alfimeprase as a therapy for ischemic stroke patients during hours three through nine following onset of symptoms, the company announced Dec. 12.